Ublituximab

DLBCL

TG Therapeutics, Inc.monoclonal_antibodyPhase 2/3Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 39/ 100
Competitive Position: 89/ 100

Competitive context

271 Active assets in the DLBCL cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE National Cancer Institute (NCI)	Phase 2/3	A
Evomela Ruijin Hospital	Phase 4	BBB
Axicabtagene Ciloleucel Ruijin Hospital	Phase 4	BBB
PREDNISONE TABLETS Beth Israel Deaconess Medical Center	Phase 4	BBB
Inno-206 Beth Israel Deaconess Medical Center	Phase 4	BBB

View all 50 →

Same molecule, other indications

Ublituximab is also rated in:

relapsing-remitting multiple sclerosisDormant

BBB

Indicative ·

72 / 100

marginal zone lymphomaDormant

B

Indicative ·

57 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

B

Indicative ·

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.